Clinical Trial Update: A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating SGN-40 in combination with Rituximab in CD20-positive follicular and marginal zone B-cell non-Hodgkin's lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• SGN-40 (dacetuzumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED